Department of Medical Biology and Genetics, Faculty of Medicine, Gazi University, Ankara 06510, Turkey.
Department of Medical Biology, Faculty of Medicine, Duzce University, Duzce 81620, Turkey.
Exp Biol Med (Maywood). 2020 May;245(9):805-814. doi: 10.1177/1535370220917367. Epub 2020 Apr 6.
Alternative agents that will increase the effectiveness of cisplatin, which are widely used in the advanced stage and metastatic bladder cancer, are being investigated. In previous studies, Cucurbitacin B (CuB), which is a natural compound from the Cucurbitaceae family has been shown to inhibit the proliferation of tumor cells and create synergistic effects with cisplatin. In this study, we investigated the synergistic effect of CuB with cisplatin for the first time in bladder cancer and models. Our findings showed that CuB treatment with cisplatin reduced cell proliferation, and reduced tumor development through activating apoptosis and autophagy via PI3K/AKT/mTOR signaling pathway. Our results showed that CuB may be a new agent that can support conventional treatment in bladder cancer. Our study is important in terms of enlightening new pathways and developing new treatment methods in the treatment of bladder cancer.
正在研究能够提高顺铂疗效的替代药物,顺铂被广泛用于晚期和转移性膀胱癌。在之前的研究中,已证实来自葫芦科的天然化合物葫芦素 B(CuB)能够抑制肿瘤细胞增殖并与顺铂产生协同作用。在这项研究中,我们首次在膀胱癌模型中研究了 CuB 与顺铂的协同作用。我们的研究结果表明,CuB 联合顺铂处理可通过激活 PI3K/AKT/mTOR 信号通路诱导细胞凋亡和自噬,从而抑制细胞增殖,减少肿瘤发展。我们的研究结果表明,CuB 可能是一种新的辅助药物,可支持膀胱癌的常规治疗。本研究对于为膀胱癌的治疗提供新的治疗途径和方法具有重要意义。